LDS/Medical Tests/Lynch Syndrome Multi Gene Panel (MLH1, MSH2, MSH6, PMS2 and EPCAM), Genomic Unity®

Lynch Syndrome Multi Gene Panel (MLH1, MSH2, MSH6, PMS2 and EPCAM), Genomic Unity®

Hereditary nonpolyposis colorectal cancer (HNPCC) can be a component of Lynch syndrome. This is a multi-organ cancer syndrome that is associated with heritable defects in DNA mismatch repair (MMR). HNPCC is an autosomal dominant genetic disease affecting many organs. The four most common DNA mismatch repair genes are MLH1, MSH2, PMS2, and MSH6. These genes are involved in repairing DNA mismatches in the cells when a mutation or damage to genes occurs. Mutations in MSH2, MLH1, MSH6, and PMS2 can result in HNPCC. Genetic and immunochemistry testing is available for MLH1, MSH2, and MSH6. Deletions within the 3' end of the EPCAM gene, which lead to inactivation of the MSH2 promotor, have also been associated with Lynch syndrome. HNPCC is estimated to account for 4% to 6% of colorectal cancers. Mutation of mismatch repair genes has been associated with other cancers.

Genetic testing for MMRs can confirm the diagnosis of HPNCC and can also identify presymptomatic individuals at risk among the patient's relatives. This test usually covers most common gene mutations (coding regions) in MLH1, MSH2, and MSH6 and most common intronic (non coding region) mutations in the 5' and 3' UTR.

For patients with a family history of HNPCC or other related cancers, early screening tests such as colonoscopy, upper endoscopy, and urinalysis done yearly can be recommended starting as early as age 20-25. Genetic testing is only suggested for those patients with a family history of HNPCC.

  • Can confirm a clinical diagnosis of HNPCC
  • Early diagnosis in family members
  • Guiding preventive measures
  • A positive result means a pathogenic mutation in the MLH1, MSH2, MSH6 or PMS2 gene was detected that is predictive of Lynch syndrome
  • A negative result does not rule out Lynch syndrome, due to the possibility of an undetectable mutation in the specific gene analyzed or a mutation in another mismatch repair gene.
  • An uncertain result means that although a gene mutation was detected, it is not certain whether it is pathogenic or benign.

Negative for mutations analyzed
 

 

 

Real Time PCR, PCR with Allele Specific Primer Extension, Pyrosequencing, Sequencing, Chip array, Immunohistochemistry, FISH.

Formalin fixed paraffin embedded (FFPE) tumor samples.

Whole blood (EDTA/lavender top tube).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable
Carcinoembryonic Antigen (CEA), Chromosomal analysis, occult blood, B-RAF mutation analysis, Microsatellite Instability/HNPCC by molecular method and by IHC, Septin 9 (SEPT9), K-RAS, EGFR Mutation Detection by molecular method, p53 by molecular method and by IHC, Ki67 by IHC, p63 by IHC.
7-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login